Nestaas eirik (25 resultados)

gebundene Ausgabe. Condición: Gut. 240 Seiten Der Erhaltungszustand des hier angebotenen Werks ist trotz seiner Bibliotheksnutzung sehr sauber und kann entsprechende Merkmale aufweisen (Rückenschild, Instituts-Stempel.). In ENGLISCHER Sprache. Sprache: Englisch Gewicht in Gramm: 460.

Hardcover. Condición: Very Good. 240 Pages. unread and unmarked.

gebundene Ausgabe. 243 Seiten Ecken/Kanten bestossen, eher guter Zustand 3540650733 Sprache: Englisch.

Hardcover: 15.2 x 1.9 x 21 cm. 1. 254 p. New! -- Neu und originalverschweißt! 9783540650737 Sprache: Englisch Gewicht in Gramm: 449.

Condición: As New. Unread book in perfect condition.

Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Paperback. Condición: New.

Condición: New.

Condición: New. In English.

Condición: Used. pp. 240 1st Edition.

Condición: New. pp. 256.

Paperback. Condición: Brand New. 256 pages. 8.26x5.83x0.58 inches. In Stock.

Condición: Used. pp. 240.

Condición: Used. pp. 240.

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book is a collection of preclinical and clinical reports on the appli cation of gene therapy to human disease. The focus of these studies is on cancer and cardiovascular disease. There are two fundamental technologies for delivering therapeutic genes to diseased ceHs: either viral vectors, as discussed by Dr. Bal main, or non-viral vector systems, as discussed by Dr. Felgner. The strengths and limitations of each of these delivery systems are charac terized. The use of a therapeutic gene to treat a disease has taken two general approaches. The first is to introduce anormal (i. e. , wild type) gene into the patient that will restore normal gene function. Dr. Weiss man has characterized the tumor suppressor gene (pS3), and has shown that it can restore normal ceH function in cancer cells. The second ap proach is to treat the disease with antisense molecules. Abnormal gene expression can be down-regulated and selectively inhibited by anti sense molecules, which can reverse the pathologie process in cancer cells. Dr. Gewirtz has demonstrated this with anti sense genes on leuke mia, while Dr. Scanlon has applied this principle using ribozymes in human carcinomas. During this symposium, Dr. Engler described clinical studies of gene therapy using growth factors to stimulate new blood vessels in patients with cardiovascular disease. Several gene therapy strategies were used for cancer: overcoming drug resistance by Dr. Bertino, a pro-drug strategy with ganciclovir by Dr.…

Taschenbuch. Condición: Neu. Gene Therapy | Robert E. Sobol (u. a.) | Taschenbuch | Ernst Schering Foundation Symposium Proceedings | xii | Englisch | 2013 | Springer | EAN 9783662035795 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Condición: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar.

Hardcover. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condición: new. Questo è un articolo print on demand.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book is a collection of preclinical and clinical reports on the appli cation of gene therapy to human disease. The focus of these studies is on cancer and cardiovascular disease. There are two fundamental technologies for delivering therapeutic genes to diseased ceHs: either viral vectors, as discussed by Dr. Bal main, or non-viral vector systems, as discussed by Dr. Felgner. The strengths and limitations of each of these delivery systems are charac terized. The use of a therapeutic gene to treat a disease has taken two general approaches. The first is to introduce anormal (i. e. , wild type) gene into the patient that will restore normal gene function. Dr. Weiss man has characterized the tumor suppressor gene (pS3), and has shown that it can restore normal ceH function in cancer cells. The second ap proach is to treat the disease with antisense molecules. Abnormal gene expression can be down-regulated and selectively inhibited by anti sense molecules, which can reverse the pathologie process in cancer cells. Dr. Gewirtz has demonstrated this with anti sense genes on leuke mia, while Dr. Scanlon has applied this principle using ribozymes in human carcinomas. During this symposium, Dr. Engler described clinical studies of gene therapy using growth factors to stimulate new blood vessels in patients with cardiovascular disease. Several gene therapy strategies were used for cancer: overcoming drug resistance by Dr. Bertino, a pro-drug strategy with ganciclovir by Dr. 256 pp. Englisch.…

Condición: New. Print on Demand pp. 256 25:B&W 5.83 x 8.27 in or 210 x 148 mm (A5) Perfect Bound on White w/Gloss Lam.

Condición: New. PRINT ON DEMAND pp. 256.

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. This book is a collection of preclinical and clinical reports on the application of gene therapy to human disease. The two methods available for delivering therapeutic genes to diseased cells, viral and non-viral vector systems, are detailed and characteriz.…

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book is a collection of preclinical and clinical reports on the application of gene therapy to human disease. The two methods available for delivering therapeutic genes to diseased cells, viral and non-viral vector systems, are detailed and characterized. Several reports describe both approaches currently used in gene therapy: the introduction of a wild-type gene to restore normal gene function in diseased cells, and the use of antisense molecules to hinder abnormal gene expression. Clinical studies detail several different strategies for the treatment of cancer and cardiovascular diseases, using genetic material as therapeutic agents. The regulatory issues governing the use of gene therapy in Europe and the United States are also presented. This book highlights the range of applications and demonstrates the rapid progress being made in the field of gene therapy.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 256 pp. Englisch.…